A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder.

Trial Profile

A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Vibegron (Primary) ; Cefalexin; Levofloxacin; Tolterodine
  • Indications Overactive bladder
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Feb 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 07 May 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 25 Jan 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top